Why the LBT Innovations share price is charging higher today

The LBT Innovations Limited (ASX: LBT) share price is storming higher today after the company announced the first sale of its automated plate assesstment system in the US.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The LBT Innovations Limited (ASX: LBT) share price is storming higher today after the company announced the achievement of a milestone in the United States.

At the time of writing, LBT Innovations shares last changed hands at 15.5 cents, representing a gain of 10.71%. This takes the company's current market capitalisation to around $36 million – so we're very much at the smaller end of the ASX here.

About LBT Innovations

LBT Innovations is a designer of advanced technology solutions for the medical industry. Its core capabilities include artificial intelligence (AI), image analysis, and software engineering solutions that improve medical diagnostic workflows.

The company's first product, MicroStreak, was a world-first in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System (APAS), is currently being commercialised through a 50%-owned joint venture company.

According to LBT, the APAS instrument is the only US FDA-cleared AI technology for automated imaging, analysis and interpretation of culture plates following incubation.

Why the LBT Innovations share price is spiking

This morning, LBT announced the first sale of an APAS Independence instrument in the US to Hennepin County Medical Centre (HCMC).

The sale of the APAS Independence has been completed following the installation of the middleware driver for APAS, which connects the instrument to HCMC's information management system. This, in turn, enables the automated reporting capability of the APAS technology. 

The APAS driver was developed by Data Innovations and has been successfully interfaced by HCMC. It is now in a testing and validation phase prior to the expected routine clinical use of the urine analysis module.

HCMC is a medium-sized clinical laboratory that provides a full range of diagnostic testing and reporting services. It processes approximately 500 specimens a day, including 300 urine plate analysis.

According to the announcement, the centre has purchased the APAS Independence to support its daily culture plate workflow. With this, HCMC has entered into an annual software license for the FDA-cleared urine analysis model and a 5-year service agreement.

Commenting on the collaboration, HCMC's director of microbiology, Dr Glen Hansen, said:

"The ability for us to automate the reading of our culture plates with the APAS Independence has increased the work efficiency through the laboratory and has motivated staff who now have more time for other activities."

Meanwhile, LBT CEO and managing director Brent Barnes said:

"We are thrilled for HCMC to be the site of our first APAS sale in the United States given their status and reputation which will no doubt help provide further commercial validation. Dr Hansen has been a great advocate for the technology and the purchase reflects the positive impact the technology has had within their lab. We continue to work hard with other laboratories in the region as we look to target further U.S. commercial sales."

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

ANZ ASX 200 banks capital return Group of investors madly grabbing for cash on city street.
Healthcare Shares

ResMed shares rebounding as investors rush to buy the dip

ResMed is rising as ASX investors buy the dip following yesterday's 13% share price dive.

Read more »

A fit man flexes his muscles, indicating a positive share price movement on the ASX market
ETFs

How to invest in US weight loss drug stocks on the ASX

Want to buy shares in the maker of Ozempic? There's an ASX ETF for that.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

ResMed share price plunges 13% as weight-loss results reawaken worries

Why are investors heading to the exits today? Let's see what's happening.

Read more »

Exhausted young Caucasian woman lying on comfortable sofa in living room sleeping after hard-working day, tired millennial female fall asleep on couch at home, take nap or daydream, fatigue concept
Healthcare Shares

ResMed shares are in a two-month lull. Is this a chance to buy?

ResMed shares are still trading below the price targets of several brokers.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Healthcare Shares

Botanix shares jump on FDA approval and $70m capital raising

Investors are responding positively to some very big news.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Botanix Pharmaceuticals share price on watch amid FDA news and 'transformative event'

Big news has just been announced from this clinical dermatology company.

Read more »

Three health professionals at a hospital smile for the camera.
52-Week Highs

3 ASX healthcare shares smashing new 52-week highs today

The buying continues for these healthcare darlings.

Read more »